Progression-free survival (PFS) by independent review results from ALLIANCE A031203 trial (CABOSUN): cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)
      Google Scholar   
Citation:
Ann Oncol vol 28 (suppl 5) mdx440.032, LBA38
Meeting Instance:
ESMO 2017
Year:
2017
Type:
Abstract
Sub type:
Poster Discussion
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
Yes
Parents:
None
Children:
2834  
Program:
OGC
Primary Committee:
GU
Sec. Committees:
   
Pharmas:
Exelixis  
Grants:
U10CA180821, U10CA180882  
Corr. Author:
 
Authors:
                       
Networks:
CA136, LAPS-IL057, LAPS-MA036, LAPS-NY016   
Study
Alliance-A031203
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords: